There are also many trials reported effects of different SGLT-2 inhibitors in HF patients, like canagliflozin (17), Dapagliflozin (9), sotagliflozin (10), luseogliflozin (12), while the others like ertugliflozin (18), ipragliflozin (19) and tofogliflozin (20) are mainly focusing on T2DM patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.